Beam Therapeutics Inc.BEAM

Beam Therapeutics Inc. is spending cash faster than a startup influencer burns through coffee: in the quarter ended March 31, 2026 the company reported revenue of $31.7 million, an operating loss of $107.2 million, a net loss of $94.3 million, and just $2.2 million of capex, while burning $128.5 million in operating cash. Diluted EPS landed at $-0.91 on 103.3 million shares, and the balance sheet still shows only $288.3 million in cash against $316.4 million in liabilities. The company’s own SEC 10-Q dryly labels the period with ‘Derivatives and Hedging (Topic 815)’ and ‘Revenue from Contracts with Customers (Topic 606)’, as if accounting chapters are footing the server bills in Durham. (source: Official SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1745999/000119312526210338/beam-20260331.htm)

Behind the glossy images of its Research Triangle Park facility and a pipeline that reads like a Marvel movie-BEAM-302 for AATD, BEAM-301 for GSDIa-the numbers tell a simpler story: Beam is still in the capital-intensive phase of gene-editing R&D, with $104.5 million spent on R&D this quarter alone and no revenue yet large enough to matter. The company’s SEC filings confirm it has sold 13.8 million shares under a Jefferies arrangement at an average of $62.75, with Jefferies entitled to up to 3% of gross proceeds as commission. Translation: the company is paying a bank to sell its shares so it can keep funding the experiment. (source: Official SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1745999/000119312526210338/beam-20260331.htm)

The operating reality is plain: Assets of $1.48 billion are propped up by $1.16 billion in shareholders’ equity, but only $288.3 million is cash-hardly a war chest for the long runway implied by the pipeline. The SEC’s company-facts JSON dutifully reflects the filings, while the company’s own site directs patient questions to an email address and shows the same pipeline image that’s been circulating since the last cycle. The filings are exhaustive; the clinical outcomes are not. (source: SEC company-facts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001745999.json; Pipeline | Beam Therapeutics, https://beamtx.com/pipeline/)

Mechanically, the stock’s liquidity is tied to the Jefferies sales agreement and the steady drip of insider trading windows disclosed on SEC Forms 4, while the clinical pipeline remains the only part of the story that hasn’t yet been priced to perfection. The SEC’s filings index confirms the routine parade of ownership disclosures, but it can’t conjure approvals, revenue, or profits that haven’t been filed yet. If you’re trading BEAM, you’re betting on the narrative, not the filings. (source: SEC EDGAR filings index, https://www.sec.gov/edgar/browse/?CIK=1745999)

What changed this week: nothing material. The SEC submissions JSON confirms the usual Forms 3, 4, and 144, while the company’s public rails continue to point to the same clinical-trial contact email, pipeline image, and manufacturing site in Research Triangle Park. In short, the evidence rail has not parsed fresh revenue, profit, approval, or clinical readouts-so the story remains unchanged, the burn continues, and the shares continue to trade on platform promise rather than balance-sheet proof. (source: SEC submissions JSON, https://data.sec.gov/submissions/CIK0001745999.json)

What remains unproven: whether any of Beam’s base-editing candidates can deliver durable clinical benefit at a dose regulators will accept, whether the manufacturing facility can scale without torching the rest of the cash, and whether the Jefferies sales arrangement can keep funding the story long enough for the plot to thicken. The SEC filings are exhaustive; the outcomes are not. (source: Official SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1745999/000119312526210338/beam-20260331.htm)

What would change the file next: top-line clinical data from BEAM-301 or BEAM-302, an FDA guidance update that clarifies the regulatory bar for base-edited therapies, or a concrete revenue-generating partnership that moves the company beyond Jefferies-style share sales and into the black. Until then, the platform’s glossy images do the walking while the balance sheet’s red ink does the talking. (source: Clinical Trials | Beam Therapeutics, https://beamtx.com/patients/clinical-trials/)